PROVECTUS BIOPHARMACEUTICALS, INC.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
PVCT$0.07+3.6%Stored close · as of Jun 30, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| March 31 | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| (Unaudited) | ||
| Assets | ||
| Current Assets: | ||
| Cash | $223,883 | $251,291 |
| Prepaid expenses and other current assets | 236,502 | 316,583 |
| Total Current Assets | 460,385 | 567,874 |
| Equipment and furnishings, less accumulated depreciation of $120,479 and $120,013, respectively | 2,534 | 3,000 |
| Operating lease right-of-use asset | 114,661 | 126,628 |
| Total Assets | $577,580 | $697,502 |
| Liabilities and Stockholders’ Deficit | ||
| Current Liabilities: | ||
| Accounts payable | $815,315 | $716,220 |
| Accrued interest | 38,300 | 23,540 |
| Accrued interest - related parties | 119,545 | 120,384 |
| Other accrued expenses | 3,568,311 | 3,161,379 |
| Notes payable | 161,265 | 217,772 |
| Convertible notes payable | 980,000 | 870,000 |
| Convertible notes payable - related parties | 1,510,000 | 1,740,000 |
| Operating lease liability, current portion | 49,025 | 48,083 |
| Total Current Liabilities | 7,241,761 | 6,897,378 |
| Notes payable, non-current portion | - | 23,621 |
| Operating lease liability, non-current portion | 66,649 | 79,221 |
| Total Liabilities | 7,308,410 | 7,000,220 |
| Commitments, contingencies, and litigations (Note 13) | - | - |
| Stockholders’ Deficit: | ||
| Preferred stock; par value $0.001 per share; 25,000,000 shares authorized; Series D Convertible Preferred Stock; 957,100 shares designated at March 31, 2026 and December 31, 2025; 956,985 shares issued and outstanding at March 31, 2026 and December 31, 2025; aggregate liquidation preference of $1,643,333 at March 31, 2026 and December 31, 2025, respectively | 957 | 957 |
| Series D-1 Convertible Preferred Stock; 23,042,900 shares designated at March 31, 2026 and December 31, 2025; 14,355,050 and 14,183,315 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively; aggregate liquidation preference of $231,040,798 and $227,778,438 at March 31, 2026 and December 31, 2025, respectively | 14,355 | 14,183 |
| Common stock; par value $0.001 per share; 1,000,000,000 shares authorized; 420,279,879 shares issued and outstanding at March 31, 2026 and December 31, 2025 | 420,280 | 420,280 |
| Additional paid-in capital | 257,043,993 | 256,179,846 |
| Accumulated other comprehensive loss | (59,906) | (60,191) |
| Accumulated deficit | (264,144,266) | (262,853,812) |
| Total Provectus Biopharmaceuticals, Inc., Stockholders’ Deficit | (6,724,587) | (6,298,737) |
| Non-controlling interest in subsidiary | (6,243) | (3,981) |
| Total Stockholders’ Deficit | (6,730,830) | (6,302,718) |
| Total Liabilities and Stockholders’ Deficit | $577,580 | $697,502 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.